2014 hot sales high purity good price Lurasidone hydrochloride CAS NO.367514-88-3

1. Superior quality 
2.Competitive price 
3. Good service 
4. Stock availability all the year around
5. Flexible payment

We accept both small orders and mass production

Company Introduction

Beijing Mesochem Technology Co., Ltd. is founded in 2009 as an independent high-tech enterprises specializing in Pharmaceutical chemicals and fine chemicals, it aims to to adapt to the business development of Beijing Huafeng United Technology Co., Ltd established in 2005.
The company locates in "Pharm Valley"'- Beijing Economic and Technological Development Zone(BDA), devotes to active pharmaceutical ingredient, intermediates and Pharmaceutical technology development services. It has independent R&D ability and right of import-export operations and has already established stable cooperation relationship with hundreds of pharmaceutical companies and research institutions both at home and abroad.
Beijing Mesochem Technology Co., Ltd has two production base at Xingan (Jiangxi Province) and Xiangyang (Hubei province), with production area about 67000 m2 and various of manufacturing equipment amount to 30000L, it has the ability of R&D, pilot production and commercial production. 80% of the products are exported to Europe, North America, South America, India and Pakistan, Southeast Asia and so on.

1. Lurasidone hydrochloride

2.White solid powder

3.assay no less than 99%

4.stock available

5.competitive price

Function:

   lurasidone characteristics of atypical antipsychotic drugs, the exact mechanisms in the treatment of schizophrenia like other atypical antipsychotics as not very clear, may be related to the dopamine D2 and serotonin (5-HT2A 5- 2A) on the antagonistic effect of receptor. For the treatment of schizophrenia, studies have reported lurasidone can improve cognitive function.
Adverse reaction: common adverse reactions are nausea, somnolence, sit not, Parkinson's disease and anxiety. Lurasidone no physical dependence. Lurasidone less cause weight gain, is not caused by glucose, lipid (Lei Zhi), change ECG and QT interval.
Contraindications: any known on ATUDA or the preparation of any of the components of hypersensitivity. At the same time, giving a strong CYP3A4 inhibitors such as [ketoconazole], ketoconazole and inducers such as rifampin, [rifampin].Cerebrovascular adverse reaction: antipsychotic use in atypical with dementia related psychosis in elderly patients treated had seen the incidence of cerebrovascular adverse events (such as increase, stroke, transient ischemic attack); neuroleptic malignant syndrome: immediate termination of treatment and close monitoring; tardive dyskinesia: such as clinical appropriate withdrawal; metabolic changes: atypical antipsychotics have accompanied by metabolic changes may increase cardiovascular / CEREBROVASCULAR risk. These metabolic changes including hyperglycemia, dyslipidemia, and weight gain.
Hyperglycemia and diabetes: monitoring in patients with hyperglycemia symptoms include polyuria, polydipsia, polyphagia, and weak. In patients with diabetes or at risk of diabetes in the regular monitoring of glucose.
Weight: weight gain recommendations once observed, clinical monitoring weight.
Hyperprolactinemia: possible prolactin elevation.
Use of antipsychotic drugs reported leukopenia, neutropenia and agranulocytosis. Pre existing low white blood cell count (WBC) or leukopenia / neutropenia during the first few months of treatment in patients with history should be regular monitoring of complete blood count (CBC) and WBC should terminate the LATUDA decreased first signs in the absence of other pathogenic factors.
Orthostatic hypotension and syncope: can cause vertigo, Heartbeat tachycardia or Beckoning bradycardia, and syncope, especially in the early stage of treatment. Have known cardiovascular or cerebrovascular disease patients with caution, and not in the use of antipsychotics in patients with in.
Seizures: a history of seizures or reduce the threshold condition used with caution in patients with epilepsy.